Abstract

Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A multi-institutional study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call